SAN DIEGO, Aug. 13, 2025 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company") today reported financial results for the second quarter of 2025. Following the completion of the sale of INBRX-101 (the "101 Transaction") by Inhibrx, Inc. (the "Former Parent")...
Related Questions
How does Inhibrx's Q2 2025 cash burn rate compare to prior quarters and to industry peers?
How did the sale of INBRX-101 affect Inhibrx's revenue and profitability for Q2 2025?
What is the expected impact of the 101 Transaction on the company’s cash position and balance sheet?
Did the company meet or miss consensus revenue and earnings per share estimates for the quarter?
What guidance did Inhibrx provide for the remainder of 2025 and FY2025, and how does it compare to previous guidance?
What is the market’s reaction to the announcement (stock price movement, volume) and is there any abnormal trading activity?
Are there any new pipeline milestones, clinical data releases, or regulatory updates mentioned that could affect future revenue?
What are the terms of the INBRX-101 transaction (valuation, earn‑outs, royalties) and how might they affect future earnings?
How does the company's current valuation (EV/EBITDA, P/E) compare with other biotech companies with similar pipelines?
What is the outlook for the remaining INBRX product candidates and their potential impact on revenue growth?
Are there any risks or uncertainties disclosed in the filing that could affect future performance (e.g., litigation, regulatory delays)?
What is the analyst consensus and target price revision, if any, following this earnings release?